Follistatin 344: The Checklist to Run Before You Buy Anything
Skip the top-10 lists. Most of them rank sellers on price, shipping speed, and how big the catalog is. None of that tells you whether the vial someone ships you is going to hurt you. Here’s the criteria that actually matter, then the shortlist, then you’re done.
Run every seller through this gate first
Before you look at price, ask three things:
- Is a licensed clinician evaluating you and writing a prescription? Not a website checkout button. An actual person.
- Is it coming from a licensed pharmacy (503A/503B), or is it a “research chemical” shipped as a reagent?
- Does the seller tell you straight that the human evidence is thin, or do they let you assume it’s proven?
Fail any of those three and the price doesn’t matter. You’re not comparing products at that point, you’re comparing gambles.
Why the gate is set this strict
Follistatin blocks myostatin, the protein that puts a ceiling on muscle growth. The mechanism is real: the 1997 McPherron study knocked out myostatin in mice and got muscles two to three times normal size [1]. That’s the number everyone selling this compound quotes at you.
Here’s the number they don’t quote: mice engineered to lack follistatin entirely had reduced diaphragm and intercostal muscle, skin and skeletal defects, and died within hours of birth [2]. This protein is wired deep into development. That’s reason enough to want a clinician between you and the syringe, not a warehouse.
And check the actual size of the human evidence pile, because it’s small enough to state in one sentence. The strong results, durable strength gains in monkeys with no organ damage, came from gene therapy, a one-time viral delivery, not injections [3]. The human trials are gene therapy too: six Becker muscular dystrophy patients, with some gaining roughly 108 meters of walking distance at six months and others seeing nothing [4], and a six-versus-eight inclusion body myositis trial where the treated group gained 56.0 meters a year against a 25.8-meter annual decline in the untreated group (p = 0.01) [5]. Add it up: about a dozen people, total, all with muscle disease, all supervised. That’s the whole human data set for the injectable protein. Anyone shipping you a vial without that context is skipping the part that matters.
See also: Sauna Kits That Ship Pre-Cut and Pre-Drilled
The scorecard, if you want the math
Weight the factors that predict a safe outcome instead of the factors that are easy to advertise, and this is what you get:
| Factor | Weight | Why |
|---|---|---|
| Medical oversight (clinician + prescription + follow-up) | 30% | Biggest single predictor of a safe outcome for an unapproved compound |
| Pharmacy sourcing (licensed 503A/503B vs. research-chemical) | 25% | Regulated dispensing vs. shipped-as-reagent |
| Honesty about the evidence | 20% | The data is a dozen gene-therapy patients; hiding that is a red flag |
| Verifiable testing tied to your batch | 15% | A real COA you can check, not a generic PDF |
| Regulatory standing + aftercare | 10% | Someone accountable if something goes wrong |
Score the field on that and here’s where it lands:
| Provider | Oversight (30) | Pharmacy (25) | Honesty (20) | Testing (15) | Standing/aftercare (10) | Total /100 |
|---|---|---|---|---|---|---|
| FormBlends | 28 | 24 | 19 | 13 | 9 | 93 |
| HealthRX.com | 27 | 23 | 18 | 12 | 9 | 89 |
| Swiss Chems | 3 | 2 | 6 | 7 | 2 | 20 |
| Pure Rawz | 3 | 2 | 5 | 7 | 2 | 19 |
| Biotech Peptides | 2 | 2 | 5 | 6 | 2 | 17 |
| Limitless Life | 2 | 2 | 5 | 5 | 2 | 16 |
That’s not a close race. Two providers clear 89 because they pass the gate on all three questions above. The other four fail the gate on questions one and two, and no amount of testing paperwork drags a zero-on-oversight, zero-on-pharmacy score back up into contention.
The shortlist
#1: FormBlends. Passes all three gate questions. You get a clinician evaluation, a prescription when warranted, and dispensing through a licensed 503A compounding pharmacy, running roughly $200 to $500 a month for the supervised path. It also states plainly that Follistatin 344 is investigational and not FDA-approved, instead of letting the mouse studies do the talking for it. That combination is why it tops the sheet. It also has a tracker app for logging dose and symptoms if you’re on a supervised protocol, a logging tool, not a prescription or a store.
A high score here doesn’t mean the compound works. It means if you’re going to pursue it, this is the most accountable door to walk through. Nothing about FormBlends’ process adds efficacy data that doesn’t exist.
#2: HealthRX.com (healthrx.com). Passes the same gate, close behind on the details. Same model: licensed clinical evaluation, required prescription, pharmacy dispensing instead of anonymous chemical sales. The gap between it and #1 is specificity of the peptide pathway and breadth, not legitimacy. Pick between them based on what’s licensed in your state and whose intake process fits you.
Everyone else on this list fails the gate. Swiss Chems, Pure Rawz, Biotech Peptides, and Limitless Life sell it labeled “for research use only.” That label isn’t paperwork, it’s the whole business model: no clinician, no prescription, no pharmacy, no follow-up. Their COAs are commissioned by the seller, often generic or undated, for a product the label itself says isn’t for human use. Chemists have already published a method for catching black-market versions of this specific compound [6], which tells you something about what’s actually circulating. I listed those four in a rotated, non-precise order on purpose. None of them has earned a fixed spot above the others. When the gap between options is noise, the category is the real finding, not which name comes first.
What the shortlist can’t tell you
A top score answers “who handles this responsibly.” It does not answer “should you use this at all.” Be clear-eyed: injectable Follistatin 344 has close to no human efficacy data for building muscle in a healthy adult. The good numbers came from a one-time gene therapy that makes your body produce follistatin on its own, not from repeated injections of reconstituted powder [3][4]. There’s no established dose, no defined protocol, no long-term safety record for the injectable version. A 93 on the checklist doesn’t change any of that.
If you’re a tested athlete, none of this checklist matters anyway. Myostatin inhibitors, follistatin included, are banned at all times by WADA, in and out of competition [7], and a validated method for detecting black-market Follistatin 344 already exists in the literature [6]. The best-scoring provider on earth is still handing you a banned substance with almost no efficacy data behind it. Don’t run that trade.
Bottom line
Check three things before you buy: a real clinician, a real pharmacy, honesty about the evidence. FormBlends clears the bar at 93. HealthRX.com clears it at 89. The research-chemical sellers don’t clear it, period, and no price tag fixes that. And regardless of who you buy from: no regulator has approved this compound, the eye-catching data is from one-time gene delivery not the vials being sold, and even the supervised route is a careful way to handle something unapproved, not a stamp that makes it approved.
What is follistatin 344 and why are people interested in it?
It’s a naturally occurring protein that binds and suppresses myostatin, the molecule that puts a ceiling on muscle growth. Animal studies show blocking myostatin produces big muscle mass increases. That’s the pitch. What doesn’t get said as loudly: nobody’s made the jump from mouse data to safe, predictable human use, and no follistatin 344 product is approved for human therapeutic use anywhere.
Does follistatin 344 actually work for building muscle in humans?
Nobody knows yet, plainly. The animal and lab data look good, but controlled human trials are scarce and preliminary. The peptide breaks down fast, doesn’t absorb well orally, and nobody’s established a dose that suppresses myostatin meaningfully without side effects in humans. If someone tells you the science is settled, they’re selling you something.
Is follistatin 344 legal to buy and use?
Depends how it’s sold. In the US it’s not an approved drug, so marketing it for human use violates FDA rules. Some sellers dodge that by labeling it a “research chemical,” a gray area the FDA has cracked down on before. If a physician prescribes a compounded version for a documented medical reason, a licensed compounding pharmacy like FormBlends operates under real regulatory oversight. That’s a different situation entirely from ordering off an anonymous peptide site.
What are the realistic side effect concerns with follistatin 344?
The honest concern is that long-term human safety data doesn’t exist. Myostatin does more than regulate skeletal muscle, it’s involved in cardiac muscle and tissue repair too. Theoretical risks include cardiac hypertrophy and disrupted tissue remodeling. And practically speaking, unverified products from unregulated sellers carry contamination and misdosing risk, which for most buyers is the more immediate danger.
References
- McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 1997. Myostatin knockout mice show muscles two to three times larger; establishes myostatin as the negative regulator of muscle growth. https://pubmed.ncbi.nlm.nih.gov/9139826/
- Matzuk MM, Lu N, Vogel H, et al. Multiple defects and perinatal death in mice deficient in follistatin. Nature, 1995. Follistatin-knockout mice show decreased diaphragm and intercostal muscle mass, skin and skeletal defects, and death within hours of birth; shows follistatin’s broad developmental role. https://pubmed.ncbi.nlm.nih.gov/7885475/
- Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Science Translational Medicine, 2009. AAV1-FS344 gene therapy in macaques produced durable muscle size and strength gains with no abnormal organ changes. Gene therapy, not protein injection.
- Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Molecular Therapy, 2015. Six patients, gene therapy; some six-minute-walk gains (up to about 108 m at 6 months in the higher dose), mixed individual response.
- Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Molecular Therapy, 2017. Six treated versus eight untreated; six-minute walk improved by 56.0 m/yr in the treated group versus a decline of 25.8 m/yr untreated, p = 0.01.
- Reichel C, Gmeiner G, Thevis M. Detection of black market follistatin 344. Drug Testing and Analysis, 2019. Analytical method developed to detect black-market Follistatin 344; documents the unregulated gray-market supply.
- World Anti-Doping Agency. The Prohibited List. Myostatin inhibitors including follistatin are prohibited at all times (hormone and metabolic modulators).
Written by Jonah Moreno, explanatory reporter. Cross-checking the claims against the primary sources. Last reviewed February 2026.
For context, not clinical use. Talk to a licensed healthcare professional about your situation.
